Literature DB >> 10662391

Measuring the effects of medication use on health-related quality of life in patients with rheumatoid arthritis. A review.

M B Nichol1, A S Harada.   

Abstract

As the treatment of rheumatoid arthritis (RA) moves towards earlier and more consistently maintained therapy, often with highly toxic medications, the importance of assessing patients' health-related quality of life (HR-QOL) is of increasing concern to healthcare providers, insurers and policy-makers. As the course of RA can extend 20 years or more, and as patient involvement in their care and evaluation increases, the goal of therapy should be to work towards the HR-QOL desired by the patient. The challenge in HR-QOL measurement is its multidimensional nature, which takes into account not only how a person functions physically, mentally and socially, but also incorporates the individual's perceived well-being in their physical, mental and social aspects of daily life. This review focuses on measuring the HR-QOL outcomes of drug therapy in RA in clinical settings as well as in clinical drug trials. The most commonly used instruments in RAHR-QOL measurement are presented, with particular attention to those that have been used to assess the impacts of drug therapy. Traditionally, RA treatment outcomes assessment has focused on physical functioning and activities of daily living. As a result, there is an abundance of instruments that have been used in RA that measure physical functioning. Social and mental functioning are being assessed more frequently as clinicians and researchers recognise the added value of assessing these dimensions in addition to physical functioning. Patient perceived well-being (especially as it relates to physical, mental and social aspects of their lives), however, is still rarely measured. We conclude that there are few validated instruments which truly assess the impact of drug therapy on HR-QOL in RA; most are intended as measures of functional or health status. In addition, few studies have been conducted in natural clinical practice settings (as opposed to controlled clinical trial settings). Further, our review reveals that the psychological and social dimensions of HR-QOL are often lacking from some of the most popular RA instruments currently in use.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10662391     DOI: 10.2165/00019053-199916050-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  74 in total

1.  Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.

Authors:  M Boers; A C Verhoeven; H M Markusse; M A van de Laar; R Westhovens; J C van Denderen; D van Zeben; B A Dijkmans; A J Peeters; P Jacobs; H R van den Brink; H J Schouten; D M van der Heijde; A Boonen; S van der Linden
Journal:  Lancet       Date:  1997-08-02       Impact factor: 79.321

Review 2.  Quantitative measures to assess, monitor and predict morbidity and mortality in rheumatoid arthritis.

Authors:  T Pincus; L F Callahan
Journal:  Baillieres Clin Rheumatol       Date:  1992-02

3.  The SCL-90 and the MMPI: a step in the validation of a new self-report scale.

Authors:  L R Derogatis; K Rickels; A F Rock
Journal:  Br J Psychiatry       Date:  1976-03       Impact factor: 9.319

4.  Measuring disease-specific quality of life in clinical trials.

Authors:  G H Guyatt; C Bombardier; P X Tugwell
Journal:  CMAJ       Date:  1986-04-15       Impact factor: 8.262

5.  The AIMS2-SF: a short form of the Arthritis Impact Measurement Scales 2. French Quality of Life in Rheumatology Group.

Authors:  F Guillemin; J Coste; J Pouchot; M Ghézail; C Bregeon; J Sany
Journal:  Arthritis Rheum       Date:  1997-07

6.  The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality.

Authors:  A Linos; J W Worthington; W M O'Fallon; L T Kurland
Journal:  Am J Epidemiol       Date:  1980-01       Impact factor: 4.897

7.  Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981-1996.

Authors:  M M Ward; J F Fries
Journal:  J Rheumatol       Date:  1998-03       Impact factor: 4.666

8.  The two-year follow-up of a randomized comparison of in-patient multidisciplinary team care and routine out-patient care for active rheumatoid arthritis.

Authors:  T P Vliet Vlieland; F C Breedveld; J M Hazes
Journal:  Br J Rheumatol       Date:  1997-01

9.  Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials.

Authors:  D T Felson; J J Anderson; R F Meenan
Journal:  Arthritis Rheum       Date:  1992-10

10.  Validity, reliability, and sensitivity to change of a French version of the arthritis impact measurement scales 2 (AIMS2) in patients with rheumatoid arthritis treated with methotrexate.

Authors:  J Pouchot; F Guillemin; J Coste; C Brégeon; J Sany
Journal:  J Rheumatol       Date:  1996-01       Impact factor: 4.666

View more
  5 in total

Review 1.  An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.

Authors:  Nick J Bansback; Dean A Regier; Roberta Ara; Alan Brennan; Kamran Shojania; John M Esdaile; Aslam H Anis; Carlo A Marra
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Iatrogenic cost factors incorporating mild and moderate adverse events in the economic comparison of aceclofenac and other NSAIDs.

Authors:  F Peris; E Martínez; X Badia; M Brosa
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 3.  The use of opioids in the treatment of osteoarthritis: when, why, and how?

Authors:  Jeremy L R Goodwin; Jan J Kraemer; Zahid H Bajwa
Journal:  Curr Rheumatol Rep       Date:  2009-02       Impact factor: 4.592

Review 4.  Patient-reported outcomes and their role in the assessment of rheumatoid arthritis.

Authors:  Deborah P Lubeck
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 5.  The use of opioids in the treatment of osteoarthritis: when, why, and how?

Authors:  Jeremy L R Goodwin; Jan J Kraemer; Zahid H Bajwa
Journal:  Curr Pain Headache Rep       Date:  2005-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.